NewcelX Prepares for Spring 2026 Conferences with Updated Corporate Strategies and Focus on Type 1 Diabetes Treatments NewcelX Ltd. has unveiled an updated corporate presentation ahead of significant investor conferences, placing emphasis on Type 1 Diabetes therapies and new expert additions.

NewcelX Prepares for Spring 2026 Conferences with Updated Corporate Strategies and Focus on Type 1 Diabetes Treatments #biotechnology #Switzerland #Zurich #Diabetes_Therapy #NewCelX

Avant Technologies Pioneers Cell-Based Diabetes Therapeutics at EPITA Symposium Avant Technologies participates in the 15th EPITA Symposium, showcasing innovative cell-based therapies aimed at treating diabetes and related disorders.

Avant Technologies Pioneers Cell-Based Diabetes Therapeutics at EPITA Symposium #Austria #Avant_Technologies #Diabetes_Therapy #EPITA_Symposium #Igls

Genprex Unveils Promising Diabetes Gene Therapy Data at ASGCT Meeting Genprex, Inc. is set to present remarkable preclinical data on GPX-002, a groundbreaking gene therapy for diabetes, during the ASGCT Annual Meeting in New Orleans.

Genprex Unveils Promising Diabetes Gene Therapy Data at ASGCT Meeting #United_States #Austin #Genprex #GPX-002 #Diabetes_Therapy